Original Article

Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3

Volume 37 · Issue 1 Publish Date: September 10, 2025
Sibel Yıldız Kaya ORCID Behice Kurtaran ORCID Nefise Öztoprak Çuvalcı ORCID Yusuf Önlen ORCID Mehmet Reşat Ceylan ORCID Esra Zerdali ORCID Nagehan Didem Sarı ORCID Ahsen Öncül ORCID Nurettin Erben ORCID Ayse Batirel ORCID Dilara İnan ORCID Süheyla Kömür ORCID Figen Sarıgül Yıldırım ORCID Hasibullah Yaqoobi ORCID Ferit Kuscu ORCID Rahmet Guner ORCID Fehmi Tabak ORCID Hep-C Türkiye Study Group
Full Text PDF
DOI

Published In

Turkish Journal of Gastroenterology

Volume 37 · Issue 1

Pages: 113-120

History

Published Online: September 10, 2025

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2025 Sibel Yıldız Kaya, Behice Kurtaran, Nefise Öztoprak Çuvalcı, Yusuf Önlen, Mehmet Reşat Ceylan, Esra Zerdali, Nagehan Didem Sarı, Ahsen Öncül, Nurettin Erben, Ayse Batirel, Dilara İnan, Süheyla Kömür, Figen Sarıgül Yıldırım, Hasibullah Yaqoobi, Ferit Kuscu, Rahmet Guner, Fehmi Tabak, Hep-C Türkiye Study Group

Sibel Yıldız Kaya ORCID
Department of Infectious Disease and Clinical Microbiology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
Behice Kurtaran ORCID
Department of Infectious Disease and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Türkiye
Nefise Öztoprak Çuvalcı ORCID
Department of Infectious Disease and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Türkiye
Yusuf Önlen ORCID
Department of Infectious Disease and Clinical Microbiology, Mustafa Kemal University Faculty of Medicine, Hatay, Türkiye
Mehmet Reşat Ceylan ORCID
Department of Infectious Disease and Clinical Microbiology, Harran University Faculty of Medicine, Şanlıurfa, Türkiye
Esra Zerdali ORCID
Department of Infectious Disease and Clinical Microbiology, Haseki Training and Research Hospital, İstanbul, Türkiye
Nagehan Didem Sarı ORCID
Department of Infectious Disease and Clinical Microbiology, İstanbul Teaching and Research Hospital, İstanbul, Türkiye
Ahsen Öncül ORCID
Department of Infectious Disease and Clinical Microbiology, İstanbul Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Türkiye
Nurettin Erben ORCID
Department of Infectious Disease and Clinical Microbiology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Türkiye
Ayse Batirel ORCID
Department of Infectious Disease and Clinical Microbiology, Kartal Dr Lütfi Kırdar City Hospital, İstanbul, Türkiye
Dilara İnan ORCID
Department of Infectious Disease and Clinical Microbiology, Akdeniz University Faculty of Medicine, Antalya, Türkiye
Süheyla Kömür ORCID
Department of Infectious Disease and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Türkiye
Figen Sarıgül Yıldırım ORCID
Department of Infectious Disease and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Türkiye
Hasibullah Yaqoobi ORCID
Department of Infectious Disease and Clinical Microbiology, Başkent University Adana Dr.Turgut Noyan Training and Research Center, Adana, Türkiye
Ferit Kuscu ORCID
Department of Infectious Disease and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Türkiye
Rahmet Guner ORCID
Department of Infectious Disease and Clinical Microbiology, Yıldırım Beyazıt University Faculty of Medicine, Ankara, Türkiye
Fehmi Tabak ORCID
Department of Infectious Disease and Clinical Microbiology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
Hep-C Türkiye Study Group
Kaya, S. Y., Kurtaran, B., Öztoprak Çuvalcı, N., Önlen, Y., Ceylan, M. R., Zerdali, E., … Study Group, H.-C. T. (2025). Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3. Turkish Journal of Gastroenterology, 37(1), 113–120. https://doi.org/10.5152/tjg.2025.24751
Endnote/Zotero/Mendeley (RIS) BibTeX
Full Text Full Text PDF

Abstract

Background/Aims: Despite the widespread use of direct-acting antivirals (DAAs), real-world data on treatment outcomes and predictors of response in hepatitis C virus (HCV) genotypes 2 and 3 remain limited, particularly in countries with heterogeneous patient populations such as Türkiye. This study evaluates the efficacy and safety of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV) genotype 2 (GT-2) and genotype 3 (GT-3) in Türkiye.

Materials and Methods: This cohort is a multicenter, retrospective, and observational study. Data from 267 GT-2 or GT-3 patients treated with a DAA were analyzed. Treatment efficacy was assessed by sustained virological response at 12 weeks after the end of treatment (SVR), and baseline demographic, clinical, and laboratory parameters were evaluated to identify factors associated with treatment response..

Results: An overall sustained virological response (SVR) rate of 95.9%, with no significant difference between GTs. The SVR rates were relatively lower in patients with cirrhosis. Prior pegylated interferon and ribavirin reduced SVR rates, particularly in males and patients with cirrhosis. The most common treatments were sofosbuvir-based regimens, which demonstrated comparable efficacy. No significant drug interactions were observed. The most commonly reported adverse events were fatigue and mild anemia, particularly in cirrhotic patients; however, these did not lead to treatment discontinuation.

Conclusion: This study supports the efficacy and tolerability of DAA regimens for these HCV GTs, thereby reinforcing their role in HCV eradication.

 

Cite this article as: Kaya SY, Kurtaran B, .uvalcı N., et al. Real-life experience of hepatitis C treatment with direct-acting antivirals in genotypes 2 and 3. Turk J Gastroenterol. 2026;37(1):113-120.

Most read articles by the same author(s)

1 2 3 > >> 
Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 37 · Issue 1
Pages 113-120
DOI 10.5152/tjg.2025.24751
History
Published Online September 10, 2025
License
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright
Copyright (c) 2025 Sibel Yıldız Kaya, Behice Kurtaran, Nefise Öztoprak Çuvalcı, Yusuf Önlen, Mehmet Reşat Ceylan, Esra Zerdali, Nagehan Didem Sarı, Ahsen Öncül, Nurettin Erben, Ayse Batirel, Dilara İnan, Süheyla Kömür, Figen Sarıgül Yıldırım, Hasibullah Yaqoobi, Ferit Kuscu, Rahmet Guner, Fehmi Tabak, Hep-C Türkiye Study Group
Affiliations
Sibel Yıldız Kaya ORCID
Department of Infectious Disease and Clinical Microbiology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
Behice Kurtaran ORCID
Department of Infectious Disease and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Türkiye
Nefise Öztoprak Çuvalcı ORCID
Department of Infectious Disease and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Türkiye
Yusuf Önlen ORCID
Department of Infectious Disease and Clinical Microbiology, Mustafa Kemal University Faculty of Medicine, Hatay, Türkiye
Mehmet Reşat Ceylan ORCID
Department of Infectious Disease and Clinical Microbiology, Harran University Faculty of Medicine, Şanlıurfa, Türkiye
Esra Zerdali ORCID
Department of Infectious Disease and Clinical Microbiology, Haseki Training and Research Hospital, İstanbul, Türkiye
Nagehan Didem Sarı ORCID
Department of Infectious Disease and Clinical Microbiology, İstanbul Teaching and Research Hospital, İstanbul, Türkiye
Ahsen Öncül ORCID
Department of Infectious Disease and Clinical Microbiology, İstanbul Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Türkiye
Nurettin Erben ORCID
Department of Infectious Disease and Clinical Microbiology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Türkiye
Ayse Batirel ORCID
Department of Infectious Disease and Clinical Microbiology, Kartal Dr Lütfi Kırdar City Hospital, İstanbul, Türkiye
Dilara İnan ORCID
Department of Infectious Disease and Clinical Microbiology, Akdeniz University Faculty of Medicine, Antalya, Türkiye
Süheyla Kömür ORCID
Department of Infectious Disease and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Türkiye
Figen Sarıgül Yıldırım ORCID
Department of Infectious Disease and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Türkiye
Hasibullah Yaqoobi ORCID
Department of Infectious Disease and Clinical Microbiology, Başkent University Adana Dr.Turgut Noyan Training and Research Center, Adana, Türkiye
Ferit Kuscu ORCID
Department of Infectious Disease and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Türkiye
Rahmet Guner ORCID
Department of Infectious Disease and Clinical Microbiology, Yıldırım Beyazıt University Faculty of Medicine, Ankara, Türkiye
Fehmi Tabak ORCID
Department of Infectious Disease and Clinical Microbiology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
Hep-C Türkiye Study Group
Cite this Article
Kaya, S. Y., Kurtaran, B., Öztoprak Çuvalcı, N., Önlen, Y., Ceylan, M. R., Zerdali, E., … Study Group, H.-C. T. (2025). Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3. Turkish Journal of Gastroenterology, 37(1), 113–120. https://doi.org/10.5152/tjg.2025.24751
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
Outlines